Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy

Journal of Clinical Virology

Volumn 38, Issue 1, 2007, Pages 32-38

  Rodríguez Torres, Maribel ^a,c   Rodríguez Orengo, José F ^b   Ríos Bedoya, Carlos F ^c   Fernández Carbia, Alberto ^d   González Lassalle, Elsa ^a   Salgado Mercado, Rosa ^a   Marxuach Cuétara, Acisclo M ^a  

^a Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d University Pathologists   (Puerto Rico)

Author keywords

HCV; HIV; Liver biopsy; Non responders; Peginterferon alfa 2a; Ribavirin

Indexed keywords

ANTIRETROVIRUS AGENT; GROWTH FACTOR; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANALYTICAL PARAMETERS; ANEMIA; ANKLE EDEMA; ARM SWELLING; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEPATITIS C; HERPES; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INFECTION; LABORATORY TEST; LACTIC ACIDOSIS; LEG FRACTURE; LEG SWELLING; LIPOATROPHY; LIPODYSTROPHY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MIGRAINE; MYALGIA; NEUROPATHY; NEUTROPENIA; ORAL BLEEDING; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RELAPSE; RISK REDUCTION; SIDE EFFECT; SINUSITIS; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TOOTH DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT DISEASE; VIROLOGY; WEIGHT REDUCTION;

ACUTE DISEASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33845317590     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.09.009     Document Type: Article

References (40)

1. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palù G., et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 5 (2005) 615-624
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States 1988, through 1994. N Engl J Med 341 8 (1999) 556-562
3. Benhamou Y., Bochet M., Di Martino V., Charlotte F., Azria F., Coutellier A., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30 (1999) 1054-1058
4. Benhamou Y., Di Martino V., Bochet M., Colombet G., Thibault V., Liou A., et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
5. Berg T., Van Wagner M., Hinrichsen H., Heintges T., Buggisch P., Goeser T., et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases (2004)
6. Bonacini M., Govindarajan S., Blatt J.M., Schmid P., Conrad A., and Lindsay K.L. Patients coinfected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 6 (1999) 203-208
7. Brau N., Bini E.J., Shahidi A., Aytaman A., Xiao P., Stancic S., et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 97 (2002) 2071-2078
8. Center for Disease Control and Prevention (CDC). 2004. Website: http://www.cdc.gov/ncidod/diseases/hepatitis/C/fact.htm.
9. Cribier B., Rey D., Schmitt C., Lang J.M., Kirn A., and Stoll-Keller F. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 9 (1995) 1131-1136
10. Di Martino, Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34 (2001) 1193-1199
11. Di Martino V., Thevenot T., Boyer N., Cazals-Hatem D., Degott C., Valla D., et al. HIV co infection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 16 (2002) 441-445
12. Diago M., Romero-Gómez M., Crespo J., et al. Peg interferon alfa-2a (40 kDa) (Pegasys) and ribavirin (Copegus) in patients infected with HCV genotype 1 and who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial. Hepatology 40 Suppl. 1 (2004) 389A
13. Drusano G.L., and Preston S.L. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 189 6 (2004) 964-970 [Epub 2004 Feb 27]
14. Enriquez J., Gallego A., Torras X., Perez-Olmeda T., Diago M., Soriano V., et al. Retreatment for 24 vs. 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 7 6 (2000) 403-408
15. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 347 (2002) 975-982
16. Gross, et al. Double dose Peg-interferon alfa-2a weight-based Ribavirin improves response for Interferon/Ribavirin non-responders with Hepatitis C: final results of RENEW study (2005), AASLD, San Francisco
17. Hadziyannis S.J., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 5 (2004) 346-355
18. Klein M.B., Lalonde R.G., and Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33 (2003) 365-372
19. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18 (2004) F27-F36
20. Laskus T., Radkowski M., Wang L.F., Vargas H., and Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis 178 (1998) 1189-1192
21. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
22. Martínez-Sierra C., Arizcorreta A., Diaz F., Roldan R., Martin-Herrera L., Perez-Guzman E., et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 36 (2003) 491-498
23. Moskovitz D.N., Manoharan P., and Heathcote E.J. High dose consensus interferon in non-responders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol 17 (2003) 479-482
24. Myers R.P., Benhamou Y., Bochet M., Thibault V., Mehri D., and Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 18 1 (2004) 75-79
25. Poynard T., Marcellin P., Bissery A., Myers R.P., Moussalli J., Degos F., et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previouslynon responsive to interferon: a randomized trial. J Viral Hepat 10 (2003) 197-204
26. Poynard T., Mathurin P., Cai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
27. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
28. ® doses of 1200 mg or 1600 mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection of high viral titer and body weight greater than 85 kg, 2004.
29. Rockstroh J.K., Mudar M., Lichterfeld M., Nischalke H.D., Klausen G., Golz J., et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 16 (2002) 2082-2085
30. ®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter Teravic-4 study. Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases (2004)
31. Sherman K.E., O'Brien J., Gutierrez A.G., Harrison S., Urdea M., Neuwald P., et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31 (1993) 2679-2682
32. Sherman K.E., Rouster S.D., Chung R.T., and Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 34 (2002) 831-837
33. Soriano V. Optiming response rates to Peg/RBV in coinfected patients: increased Ribavirin dosing; extending therapy duration. Highlights of the 2nd International Workshop on HIV and Hepatitis Coinfection, 2006.
34. Soriano V., Perez-Olmeda M., Rios P., Nunez M., Garcia-Samaniego J., and Gonzalez-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 20 4 (2004) 351-353
35. Teuber G., Pascu M., Berg T., Lafrenz M., Pausch J., Kullmann F., et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 39 4 (2003) 606-613
36. Thuluvath P.J., Pande H., and Maygers J. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin. Dig Dis Sci 48 (2003) 594-597
37. Tien P.C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol 100 10 (2005) 2338-2354
38. Torriani F.J., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 5 (2004) 438-450
39. World Health Organization. Hepatitis: 170 million infected worldwide and still no vaccine. WHO Press Release. No. 36. May 1, 1998.
40. Zein N.N. The epidemiology and natural history of hepatitis C virus infection. Cleve Clin J Med 70 Suppl. 4 (2003) S2-S6